Wellington Partners
A promising prophylactic vaccine candidate against Chikungunya fever will be tested from August on in a Phase II clinical study in Puerto Rico, a Chikungunya fever endemic area.
4SC AG announced the completion of its capital increase resolved on 12 June 2017 to continue to advance its drug development programs for resminostat, 4SC-202 and 4SC-208.
Sponsored by the National Institutes of Health, Themis Bioscience started a Phase II trial of its Chikungunya vaccine on a candidate in the U.S.
Page 10 of 19
